EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma

Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, Evan Seffar, Mark A Dickson, Viswatej Avutu, Lauren B Banks, Jason E Chan, Ping Chi, Mrinal M Gounder, Ciara M Kelly, Mary L Keohan und 14 weitere

Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014346

DOI: 10.1136/jitc-2025-014346 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.05.2026. Verfasst von Evan Rosenbaum und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Liposarcoma, Piperazines, Pyridines. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH/NCI, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflammation and may synergize with immune checkpoint inhibitors.

Methods

This non-randomized, open-label, phase 2 study was conducted at Memorial Sloan Kettering Cancer Center. Patients with metastatic or unresectable DDLPS, or those expected to benefit from systemic therapy prior to surgery, were eligible. Patients received palbociclib (125 mg orally, days 1–21 of a 28-day cycle) plus retifanlimab (500 mg intravenous flat dose every 4 weeks). The primary endpoint was to assess the best objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Results

30 patients were treated and evaluable. Median age was 61 years (range 36–81), 67% were male, and 63% were treatment-naive. The median follow-up was 14.8 months. ORR was 20% (95% CI 8% to 39%) and the clinical benefit rate was 53% (95% CI 34% to 72%). Median progression-free survival and overall survival were 4.8 (95% CI 1.71 to 15.7) and 27 months (95% CI 21.7 to not reached (NR)), respectively. Median duration of response was 18.4 months (95% CI 9.4 months to NR). Grade ≥3 treatment-related adverse events occurred in 61% of patients, including one Grade 4 neutropenia. There were no Grade 5 events. Retifanlimab and palbociclib were discontinued due to toxicity in 23% and 17% of patients, respectively. Tumor sequencing identified JUN amplification in 6 of 14 patients with progressive disease versus 2 patients with stable disease or partial response. Patients with progressive disease had a higher median copy number alteration burden compared with those with stable disease or partial response.

Conclusions

Palbociclib plus retifanlimab demonstrated deep and durable responses in a subset of patients with advanced DDLPS, with an ORR exceeding that historically observed with either agent alone. Adverse events were generally manageable. Copy number alteration burden and JUN amplification merit further evaluation as potential biomarkers of resistance. Trial registration number https://clinicaltrials.gov/study/NCT04438824 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLiposarcomaPiperazinesPyridinesAntibodies, Monoclonal, HumanizedAdultAgedAged, 80 and overFemaleHumansMaleMiddle Aged

Stichwörter der Autor:innen

Combination therapyImmunotherapySolid tumor

Substanzen

palbociclibPiperazinesPyridinesretifanlimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department on Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • NIH/NCI
  • U.S. Food and Drug Administration
  • Cycle for Survival
  • Geoffrey Beene Foundation

Zitieren

APA

Rosenbaum, E., Seier, K., Gularte-Mérida, R., Seffar, E., Dickson, M. A., Avutu, V., Banks, L. B., Chan, J. E., Chi, P., Gounder, M. M., Kelly, C. M., Keohan, M. L., Maki, R. G., Movva, S., Reed, D., Desir, R., Biniakewitz, M., Cho, J. M., Duchemin, M., …, & D'Angelo, S. (2026). Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. Journal for ImmunoTherapy of Cancer, 14(5), e014346. https://doi.org/10.1136/jitc-2025-014346

Vancouver

Rosenbaum E, Seier K, Gularte-Mérida R, Seffar E, Dickson MA, Avutu V, et al. Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014346. doi:10.1136/jitc-2025-014346

BibTeX
@article{Rosenbaum2026,
  author = {Rosenbaum, Evan and Seier, Kenneth and Gularte-Mérida, Rodrigo and Seffar, Evan and Dickson, Mark A and Avutu, Viswatej and Banks, Lauren B and Chan, Jason E and Chi, Ping and Gounder, Mrinal M and Kelly, Ciara M and Keohan, Mary L and Maki, Robert G and Movva, Sujana and Reed, Damon and Desir, Rhoena and Biniakewitz, Matthew and Cho, Jae-Mun and Duchemin, Michele and Erinjeri, Joseph P and Lefkowitz, Robert A and Koff, Andrew and Singer, Samuel and Tap, William and Qin, Li-Xuan and D'Angelo, Sandra},
  title = {Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {e014346},
  doi = {10.1136/jitc-2025-014346}
}
Kostenlos starten →